Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

Crispr Therapeutics AG (CRSP) stock saw a modest uptick, ending the day at $40.49 which represents a slight increase of $0.49 or 1.23% from the prior close of $40. The stock opened at $40 and touched ...

EST Cathie Wood’s ARK Investment buys 187K shares of Crispr Therapeutics (CRSP) today Published first on TheFly – the ultimate source for ...

Cancer is rarely discussed alongside liposuction or plastic surgery. However, a groundbreaking approach to cancer treatment ...

Scientists at UC San Francisco have pioneered a groundbreaking approach to fighting cancer using engineered fat cells. By ...

Group Dinner Meeting to be held in New York on February 5 at 6 pm hosted by Truist. Maximize Your Portfolio with Data Driven Insights:Leverage ...

H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Crispr Therapeutics (CRSP) with a Buy rating and $65 price target The firm says ...

Stanford researchers introduced affordable gene-editing kits ready for the classroom, aiming to make the field more accessible for high school students.

Argentine scientists created the world's first genetically edited horse using CRISPR-Cas9 technology. Next projects include gene editing in pigs and cows.

It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.

Liposuction and plastic surgery aren't often mentioned in the same breath as cancer. But they are the inspiration for a new approach to treating cancer that uses engineered fat cells to deprive tumors ...